Publications

Adriana Boateng-Kuffour 1, Caitlin S Kelly 2, Huyen T Nguyen 2, Nanxin Li 3, Keval Chandarana 3, Katherine S Chapman 2, Liang Chen 3, Emilee M Cornelius 2, Wendy A Wolf 2, Beth Barber 3, William H Polonsky 4 Abstract Introduction: This study aimed to examine psychosocial well-being, quality of life (QoL), and productivity in people with type 1 diabetes (pwT1D) who were experiencing recurrent severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia (IAH), despite using continuous glucose monitors (CGMs). Methods: The

Tricia S Tang 1, Gerri Klein 2, Lawrence Fisher 3, Jennifer C Davis 4, Linda Li 5, Matthias Görges 6, Jane Yardley 7, William H Polonsky 8, Danielle Hessler 9, Deanne Taylor 10, Akshay Jain 11, Joel Singer 12, Logan McLean 13, Tara Klassen 14 Abstract Peer support and digital technology are two promising strategies to address psychosocial needs in type 1 diabetes (T1D). REACHOUT is a mobile app designed to deliver peer-led mental health support to adults with T1D living in British Columbia. This report describes

William H Polonsky 1, Taylor L Clark 1, Emily C Soriano 2, Andrew Edgington 3, Cameron M Bennett 4, Amy E Fox 4, Thomas Grace 5 Abstract Introduction: Although continuous glucose monitoring (CGM) in adults with type 2 diabetes (T2D) has known glycemic benefits, the underlying behavioural and psychosocial processes driving these outcomes remain poorly understood. We examined how CGM influences patient-reported outcomes and whether changes in those outcomes predict glycemic improvement. Research design

Adriana Boateng-Kuffour 1, Caitlin S Kelly 2, Huyen T Nguyen 2, Keval Chandarana 3, Katherine S Chapman 2, Liang Chen 3, Emilee M Cornelius 2, Wendy A Wolf 2, William H Polonsky 4 Abstract Introduction: Although type 1 diabetes (T1D) technology has improved health outcomes for many, some people continue to experience severe hypoglycemic events (SHEs). This study reviews the history of SHEs and impaired awareness of hypoglycemia (IAH) compound risk for future SHEs, and describes the lived

Elizabeth Holmes-Truscott, Emmanuel Ekpor, Eloise Litterbach, Renza Scibilia, Partha Kar, Jane K Dickinson, Susan Guzman, Matthew Garza, Mariam Asaad, Mark T U Barone, Chitra Selvan, Tejal Lathia, Amy McInerney, Peter Senior, Timothy Skinner, Jane Speight © 2026 The Author(s). Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. Abstract Language profoundly shapes how diabetes is perceived, experienced and managed, with the potential to perpetuate stigma or promote dignity and respect.

Susan Guzman · Natalie Bellini · Lucille Hughes · Pasha Javadi ·Camilla Schanche · Maria Muccioli · Lori Berard Received: December 1, 2025 / Accepted: January 12, 2026 © The Author(s) 2026 Abstract Introduction: Effective insulin therapy relies on proper injection technique and the correct use of insulin delivery devices. Despite recommendations for a single-use device, the pen needle reuse

Korey K Hood, William H Polonsky Abstract Barriers to insulin therapy remain a critical challenge for individuals with insulin-treated diabetes, contributing to suboptimal clinical outcomes. The Afrezza® inhaled insulin system, with Technosphere® insulin (TI), is a promising alternative to subcutaneous insulin injections, offering a rapid pharmacokinetic profile and ease of use. Clinical studies demonstrate comparable HbA1c reductions, fewer hypoglycemic events, and

Authors: Emily C. Soriano, William Polonsky, Taylor L. Clark, Mariya Chichmarenko, Haley Sandoval, Alessandra Bastian, Addie L. Fortmann , Andrew Kwist, Fleur Levrat-Guillen Abstract OBJECTIVE Continuous glucose monitoring (CGM) improves type 2 diabetes (T2D) outcomes, but how this is achieved remains unclear. We explored how CGM affects diabetes-related attitudes and behavior, and whether these changes are associated with engagement in self-management

Authors: William H Polonsky, Emily C Soriano, Fleur Levrat-Guillen, Mariya Chichmarenko, Haley Sandoval, Alessandra Bastian, Addie L Fortmann, Andrew Kwist, Michael Vallis Abstract Background: Continuous glucose monitoring (CGM) promotes glycemic benefits in adults with type 2 diabetes (T2D), including insulin users as well as noninsulin users, often with minimal professional support. To investigate whether these benefits may stem from increased user engagement in self-management, we conducted a randomized controlled

Authors: Sufyan Hussain, William Polonsky,  Renza Scibilia, Timor Glatzer  Abstract Advances in diabetes technologies such as continuous glucose monitoring (CGM) have provided significant opportunities to improve glycemic and quality-of-life outcomes for people with type 1 diabetes (T1D). The ambulatory glucose profile and the introduction of glucose thresholds helped a lot to identify patterns, which was the first step toward improving hyper-and hypoglycemia